Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
HANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- Jiuzi Holdings, Inc. (NASDAQ: JZXN, hereinafter referred to as the "Company") today elaborated…
GUANGZHOU, China, Oct. 13, 2025 /PRNewswire/ -- The 138th China Import and Export Fair (Canton Fair) is set to open…
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…
KIGALI, Rwanda, Oct. 6, 2025 /PRNewswire/ -- Huawei and Rwanda's Ministry of Education announced the completion of the first phase of…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
GENEVA, Sept. 24, 2025 /PRNewswire/ -- Just days after officially announcing her candidacy for the FIA Presidency, Swiss racing driver and entrepreneur…
As part of New York Climate Week, LanzaJet's CEO addressed the President of the Republic of Kazakhstan and met with…